Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis

BACKGROUND: Radioligand therapy with [(177)Lu]Lu-PSMA-617 is efficacious for the treatment of patients with metastasized castration-resistant prostate cancer (mCRPC). Various studies have evaluated the efficacy and safety of [(177)Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval...

Descripción completa

Detalles Bibliográficos
Autores principales: Seifert, Robert, Kessel, Katharina, Schlack, Katrin, Weckesser, Matthias, Bögemann, Martin, Rahbar, Kambiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338828/
https://www.ncbi.nlm.nih.gov/pubmed/32062682
http://dx.doi.org/10.1007/s00259-020-04703-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338828/
https://www.ncbi.nlm.nih.gov/pubmed/32062682
http://dx.doi.org/10.1007/s00259-020-04703-3

Ejemplares similares